66491-03-0

Basic information

• Product Name: 7-AMINO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE
• Synonyms: 7-AMINO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE;7-aMino-3;1(2H)-Isoquinolinone, 7-aMino-3,4-dihydro-;7-Amino-3,4-dihydro-1(2H)-isoquinolinone
• CAS NO: 66491-03-0
• Molecular Formula: C₉H₁₀N₂O
• Molecular Weight: 162.19
• Mol File: 66491-03-0.mol

Chemical Properties

• Melting Point: 123-125 °C
• Boiling Point: 495.9°C at 760 mmHg
• Flash Point: 253.7°C
• Appearance: /
• Density: 1.237g/cm³
• Vapor Pressure: 5.69E-10mmHg at 25°C
• Refractive Index: 1.621
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 14.96±0.20(Predicted)
• CAS DataBase Reference: 7-AMINO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-AMINO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE(66491-03-0)
• EPA Substance Registry System: 7-AMINO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE(66491-03-0)

Safety Data

• Hazardous Substances Data: 66491-03-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
7-AMINO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE is used as a reactant in the preparation of dihydroisoquinolinones. These dihydroisoquinolinones are potent inhibitors of poly(ADP-ribose) polymerase (PARP), an enzyme that plays a crucial role in DNA repair and regulation of cell death. By inhibiting PARP, these compounds can potentially enhance the effectiveness of certain cancer treatments, particularly in tumors with DNA repair deficiencies.
The application of 7-AMINO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE in the pharmaceutical industry is primarily focused on the development of novel therapeutic agents for cancer treatment. Its role in the synthesis of PARP inhibitors highlights its importance in the ongoing research and development of targeted cancer therapies.

InChI:InChI=1/C9H10N2O/c10-7-2-1-6-3-4-11-9(12)8(6)5-7/h1-2,5H,3-4,10H2,(H,11,12)

Upstream product

• 22245-96-1 7-nitro-3,4-dihydro-2H-isoquinolin-1-one 
• 91-21-4 1,2,3,4-tetrahydroisoquinoline 
• 1196-38-9 3,4-dihydroisoquinolin-1(2H)-one 
• 6552-60-9 3,4-dihydro-2H-isoquinoline-1-thione 
• 2257-09-2 Phenethyl isothiocyanate 
• 86288-79-1 2,7-Dinitro-3,4-dihydroisocarbostyryl 
• 6970-83-8 ethyl-N-(2-phenethyl)carbamate 
• 64-04-0 phenethylamine 
• 83-33-0 inden-1-one 

Downstream Products

• 66491-04-1 7-iodo-3,4-dihydro-1(1H)-isoquinolinone 
• 1196-38-9 3,4-dihydroisoquinolin-1(2H)-one 
• 891782-60-8 7-bromo-3,4-dihydroisoquinolin-1(2 H)-one 
• 709040-12-0 1-(8-amino-1-oxo-1,2,3,4-tetrahydro-isoquinolin-7-yl)-3-(2,6-dichloro-phenyl)-thiourea 
• 1027936-01-1 [1-Oxo-7-(1-trityl-1H-imidazol-4-yl)-3,4-dihydro-1H-isoquinolin-2-yl]-acetic acid 
• 183622-32-4 ethyl 7-(1-trityl-4-imidazolyl)-3,4-dihydro-1(1H)-isoquinolinone-2-acetate 
• 1028295-53-5 4-{2-[((R)-1-Ethoxycarbonylmethyl-3-phenyl-propylcarbamoyl)-methyl]-1-oxo-1,2,3,4-tetrahydro-isoquinolin-7-yl}-piperazine-1-carboxylic acid tert-butyl ester 
• 1027838-11-4 (S)-3-{2-[1-Oxo-7-(1-trityl-1H-imidazol-4-yl)-3,4-dihydro-1H-isoquinolin-2-yl]-acetylamino}-3-pyridin-3-yl-propionic acid ethyl ester 
• 1026704-88-0 4-{2-[((S)-2-Benzenesulfonylamino-2-ethoxycarbonyl-ethylcarbamoyl)-methyl]-1-oxo-1,2,3,4-tetrahydro-isoquinolin-7-yl}-piperazine-1-carboxylic acid tert-butyl ester 
• 182198-53-4 L-767,679 
• 22245-96-1 7-nitro-3,4-dihydro-2H-isoquinolin-1-one 
• 62541-63-3 5-Iodo-2-(2-pyrrol-1-ylethyl)benzoic acid 
• 62541-67-7 2-(2-Pyrrol-1-ylethyl)-5-nitro benzoic acid 
• 62541-66-6 2-(2-Aminoethyl)-5-nitrobenzoic acid 

Relevant articles and documents

1,2,4-Triazole-3-Thione Analogues with a 2-Ethylbenzoic Acid at Position 4 as VIM-type Metallo-β-Lactamase Inhibitors

Metallo-β-lactamases (MBLs) are increasingly involved as a major mechanism of resistance to carbapenems in relevant opportunistic Gram-negative pathogens. Unfortunately, clinically efficient MBL inhibitors still represent an unmet medical need. We previou

Cyclic-fused ASK1 inhibitor and application thereof

The invention relates to a cyclic-fused ASK1 inhibitor and application thereof, and particularly to a compound shown in formula (I), a pharmacologically acceptable salt and ester thereof, and a stereisomer thereof. The invention further relates to a preparation method of the compound, a pharmaceutic preparation and a pharmaceutical composition containing the compound. The compound of the inventionis capable of effectively inhibiting phosphorylation of amino acid of ASK1, and inhibiting the activation of the ASK1, thereby can be used for treating and/or preventing ASK1-mediated diseases and related diseases.

PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a pyrazolopyrimidine derivative, a preparation method thereof and a pharmaceutical composition comprising the same as an active ingredient for the prevention or treatment of cancer, autoimmune disease and brain disease. The pyrazolopyrimidine derivative of the present invention exhibits excellent Bruton's tyrosine kinase inhibition activity, so that it can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.

Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors

Inhibitors of Factor VIIa (FVIIa), a serine protease in the clotting cascade, have shown strong antithrombotic efficacy in preclinical thrombosis models with minimal bleeding liabilities. Discovery of potent, orally active FVIIa inhibitors has been largely unsuccessful because known chemotypes have required a highly basic group in the S1 binding pocket for high affinity. A recently reported fragment screening effort resulted in the discovery of a neutral heterocycle, 7-chloro-3,4-dihydroisoquinolin-1(2H)-one, that binds in the S1 pocket of FVIIa and can be incorporated into a phenylglycine FVIIa inhibitor. Optimization of this P1 binding group led to the first series of neutral, permeable FVIIa inhibitors with low nanomolar potency.

A kind of diaryl hydanto?n derivatives, its preparation method, pharmaceutical composition and application

Provided are a compound as represented by formula I, or pharmaceutically acceptable salt, solvate, precursor drug, stereoisomer, tautomer, polymorph or metabolite thereof, pharmaceutical composition containing same, and uses thereof in the preparation of drugs for treating androgen receptor related diseases.

Discovery of novel P1 groups for coagulation factor VIIa inhibition using fragment-based screening

A multidisciplinary, fragment-based screening approach involving protein ensemble docking and biochemical and NMR assays is described. This approach led to the discovery of several structurally diverse, neutral surrogates for cationic factor VIIa P1 group

17a-HYDROXYLASE/C17,20-LYASE INHIBITORS

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.

METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES

Compounds of the present invention find utility in the treatment of hyperproliferative diseases, mammalian cancers and especially human cancers including but not limited to malignant, melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, cervical carcinomas, metastasis of primary tumor sites secondary sites, myeloproliferative diseases, chronic myelogenous leukemia, acute lymphocytic leukemia, papillary thyroid carcinoma, non small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, thyroid cancer, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, i.e. diabetic retinopathy and age-related macular degeneration, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, human inflammation, rheumatoid spondylitis, ostero-arthritis, asthma, gouty arthritis, sepsis, septic shock, endotoxic shock, Gram-negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, stroke, reperfusion injury, neural trauma, neural ischemia, psoriasis, restenosis, chronic obstructive pulmonary disease, bone resorptive diseases, graft-versus-host reaction, Crohn's disease, ulcerative colitis, inflammatory bowel disease, pyresis, and combinations thereof, a disease caused by c-ABL kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, c-KIT kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, VEGFR kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, PDGFR kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, FLT-3 kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, TIE-2 kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, TRK kinases, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, c-MET kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, or a disease caused by a HER kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof.

17α-HYDROXYLASE/C17,20-LYASE INHIBITORS

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.

BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS

The present invention provides novel bicyclic lactams derivatives, and analogues thereof, of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables A, B, C, W, Y, Z1, Z2, Z3, Z4, R8, and R9 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.